KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the
treatment of patients with relapsed or refractory small cell lung cancer.
This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a
different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms
from Part 1.